Until recently, several studies have provided increasing evidence at the gene, mRNA, and protein levels unveiling the role of CDK5 in human cancers, including BC, non‐small cell lung cancers (NSCLCs), and brain cancers.[8] It has been proven that CDK5 inhibition contributes to eliminate the progression of certain cancers and overcome the resistance to anticancer therapies efficiently.[8] These investigations indicated the possibility that CDK5 could be an intriguing drug target. The gene discussed is CDK5; the disease is lung cancer.